Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Mirabegron

Drug and asset intelligence for Mirabegron with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Recent signals(2)

RegulatoryAugust 2, 2026

FDA Approval Application for Mirabegron Submitted by Deva Holding

The FDA has received an application (ANDA219941) for Mirabegron from Deva Holding, currently under standard review.

StrategyJuly 12, 2026

FDA Grants Approval for Mirabegron ANDA219941 by Deva Holding AS

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219941 for Mirabegron submitted by Deva Holding AS.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Mirabegron

July 12, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Overactive Bladder →
Urology →
Urology · Overactive Bladder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.